Tags : Updates

Biosimilars

Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar

Revance to get $25M upfront, milestone payments upon achievement of additional clinical, regulatory and sales targets, plus sales royalties in all relevant markets and will be finalized till Apr 30, 2020 In Feb 2018, Revance and Mylan signed global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA) […]Read More

Biosimilars

Revance and Mylan Provide Updates on Development BOTOX (onabotulinumtoxinA) Biosimilar

Revance to get $25M upfront, milestone payments upon achievement of additional clinical, regulatory and sales targets, plus sales royalties in all relevant markets and will be finalized till Apr 30, 2020 In Feb 2018, Revance and Mylan signed global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA) […]Read More